Product | Peg Modified Single Walled CNT | |
Stock No | NS6130-06-681 | |
CAS | 308068-56-6 | Confirm |
Diameter | <5nm | Confirm |
Length | 20-30µm | Confirm |
Purity | >99% (SWCNT) | Confirm |
Amorphous carbon | 1% | Confirm |
Residue ( calcination in air) | <1% | Confirm |
SSA | 350-450* m²/g | Confirm |
Bulk Density | 0.05-0.17 g/cm³ | Confirm |
Real Density | 2-3 g/cm³ | Confirm |
Charging * | 2180 (Capacity: mA h/g) | Confirm |
Discharging* | 534 (Capacity: mA h/g) | Confirm |
Volume Resistivity | 0.1-0.15 Ω.cm ( measured at pressure in powder) | Confirm |
Quality Control | Each Lot of was tested successfully | |
Main Inspect Verifier | Manager QC |
The unique properties of Nanoshel’s Peg-Modified Biopharmaceuticals CNT make them a highly interesting and demandable nanocarrier in the field of nanoscience. Peg-Modified Biopharmaceuticals CNT facilitate efficient delivery of therapeutics like drugs, proteins, genes, nucleic acids, vitamins and lot more. Even though highly beneficial, the biocompatibility of CNTs is a major issue in their questioning their potential application in targeting drug delivery. A well-established mechanism for cellular internalization is an insistent need to attain a more efficient and targeted delivery.
Peg-Modified Biopharmaceuticals CNT have attracted the attention of scientists because of their unique electronic, magnetic, optical, mechanical, and chemical properties. However, their poor solubility in solvents, especially in water, limits their applications in several promising fields such as biomedicine, biomedical imaging, and cancer therapy.
Peg-Modified Biopharmaceuticals CNT on dendrimer has become an established and highly refined technology for delivery of bioactives. Dendrimers provide an ideal platform for delivery of bioactive as they represent well-defined, highly branched, nanoscale architecture with several modifiable surface groups. However, the actual potential of dendrimers is not realized due to toxicity limitations. Peg-Modified Biopharmaceuticals CNT molecules are nontoxic, non-immunogenic, and non-antigenic; highly water soluble, FDA approved and is endowed with tremendous potential to impart these properties to other biomolecules through the process of PEGylation.
Peg-Modified Biopharmaceuticals CNT dendrimer-mediated drug delivery overcomes the shortcomings of dendrimer reticuloendothelial system (RES) uptake, drug leakage, immunogenicity, hemolytic toxicity, cytotoxicity, hydrophobicity, facilitates the solubilization as well as raises the overall aptitude for DNA transfection, siRNA delivery, transepithelial transport and tumor targeting. This review focuses on various types of PEGylated dendrimer with a detailed note on various modes of PEG usage as well as their influence on various biopharmaceutical properties of dendrimer.
Peg-Modified Biopharmaceuticals CNT Drug delivery present several drawbacks, mainly due to off-target effects that may originate severe side and toxic effect to healthy tissues. Parallel to the development of novel more effective drugs, particular effort has been dedicated to develop and optimize drug delivery vehicles capable of specifically targeting the required tissue/organ and to deliver the cargo only where and when it is needed.
Nanoshel’s Product Categories Link:
Peg Modified Single Walled CNT (99%, Dia:<5nm, Length: 20-30µm)